TAKEDA PHARMA A/S: Financial statements 2025
CVR: 16406899
Source: annual report 2025, Danish Business Authority
01/04/2024 – 31/03/2025
TAKEDA PHARMA A/S (CVR 16406899) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 1,102,419,000 and a net result of DKK 12,162,000 compared with DKK 261,222,000 the year before. That is a decrease of 1.5% compared with the year before. The profit margin was 1.1%. Equity in the 2025 report amounted to DKK 368,294,000. The solvency ratio was 63.4%. The company had 68 employees in the financial year.
- Revenue
- DKK 1,102,419,000
- Gross Profit
- DKK 119,035,000
- Profit/Loss
- DKK 12,162,000
- Equity
- DKK 368,294,000
- Total Assets
- DKK 581,334,000
- Employees
- 68
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 1.1B | 119M | 12.2M | 368.3M | 68 |
| 2024 | 1.1B | 437.7M | 261.2M | 356M | 68 |
| 2023 | 1.1B | 120.6M | 13.6M | 94.9M | 70 |
| 2022 | 910.1M | 154M | 31.8M | 81.2M | 180 |
| 2021 | 1.9B | 1.1B | 667.7M | 1B | 174 |
Official annual report
How creditworthy is TAKEDA PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
TAKEDA PHARMA A/S has won the tender "Amgros 2026 1.1183.b" issued by Amgros I/S worth 142,800,000 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2026 2.290.b" issued by Amgros I/S worth 88,050,546 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2026 2.690.b" issued by Amgros I/S worth 217,081,515 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2026 1.617.b" issued by Amgros I/S worth 43,827,250 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2026 1.463.a" issued by Amgros I/S worth 70,800,000 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2026 1.700.a" issued by Amgros I/S worth 245,033,539 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2026 1.460.a" issued by Amgros I/S worth 104,000,000 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2026 1.462.a" issued by Amgros I/S worth 27,100,000 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2025 1.1001.b" issued by Amgros I/S worth 1,661,800,000 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2025 1.1461.a" issued by Amgros I/S worth 462,000,000 DKK.
About TAKEDA PHARMA A/S
TAKEDA PHARMA A/S is a Danish company of the type Aktieselskab based in Vallensbæk Strand, founded in 1984. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named NYCOMED DANMARK ApS and NYCOMED DANMARK A/S. The management consists of Enor Cerimagic. The board consists of Koki Sato (chair), Enor Cerimagic, Jesper Lindahl and Malene Kelstrup. The company is owned by Takeda Pharmaceuticals International AG. The company has 79 employees (2026). In 2026, the company reported revenue of DKK 1,112,753,000 and a net result of DKK 88,641,000 compared with DKK 12,162,000 the year before. Equity in the 2026 report amounted to DKK 456,501,000.